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The apical membrane antigen 1 of Plasmodium falciparum is one of the leading candidate antigens being developed as a vaccine to prevent malaria. This merozoite transmembrane protein has an ectodomain that can be divided into three subdomains ( Several malaria surface proteins expressed during different stages of the parasite's life cycle have been identified and are being developed as vaccine target antigens. It has been demonstrated that antibodies against membrane proteins of malaria merozoites can, in some cases, block parasite invasion of the erythrocyte (10, 11, 15, 23, 27, 30, 32) . One such recombinant vaccine being developed is based on the asexual blood stage integral membrane protein apical membrane antigen 1 (AMA-1) because antibodies to the protein effectively inhibited parasite invasion of erythrocytes in vitro (26, 30, 31, 33) . The role of AMA-1 in invasion is further supported by the fact that passive transfer of strain-specific anti-AMA-1 antibodies to Plasmodium chabaudi-infected mice protected against lethal parasitemia (1) .
AMA-1 of P. falciparum is a highly conserved 83-kDa transmembrane protein containing cytoplasmic, transmembrane, and ectodomain regions (28) . It is synthesized in merozoites, localized in the micronemes until merozoite release, and then rapidly translocated onto the merozoite surface (4, 25, 35) . The amino acid sequence of the ectodomain contains 16 cysteine residues that are cross-linked by eight disulfide bonds. The disulfide bond structure suggests that the ectodomain is composed of three distinct subdomains, domain I, domain II, and domain III (D I, D II, and D III) (13) . There is evidence that during translocation onto the merozoite surface, AMA-1 is proteolytically cleaved into smaller fragments (8, 16, 17, 25) .
Studies of animal malarias have heightened interest in the development of AMA-1 as a vaccine for human malaria. Immunization with purified recombinant AMA-1 is protective against the simian malaria parasites P. knowlesi (6) and P. fragile (2) and the rodent malaria parasites P. chabaudi (1) and P. yoelii (26) . However, the protection was parasite strain specific, suggesting that the protective immune responses were directed toward the polymorphic regions of AMA-1 (5). Protective antibody-mediated immune responses induced against AMA-1 have repeatedly been shown to be directed against conformational epitopes that are dependent on disulfide bond stabilized conformations (1, 2, 5-7, 14, 21, 26) . While the amino acid divergence observed among different isolates of P. falciparum AMA-1 has been small (ϳ5%), the changes are significant enough, in most cases, to dramatically affect the cross-strain recognition by heterologous protein-induced antibodies (19) . The emergence of these differences, at least in D I, has recently been shown to be correlated with symptomatic malaria cases (3). We recently completed the production and purification of an antimalaria vaccine based on the AMA-1 ectodomain from P. falciparum (3D7) (7) . Immunization of rabbits with purified protein induced the production of antibodies that significantly (Ͼ80%) inhibited parasites in an in vitro growth and invasion assay (GIA). The same level of inhibition in the GIA was observed with whole antibodies and Fab fragments of the antibodies (8) . In addition, monoclonal antibodies (MAb) have been produced against the ectodomain that significantly block invasion of red blood cells by merozoites in the GIA (20) . To better understand how antibodies to each of the subdomains of the ectodomain of AMA-1 contribute to the growth-inhibitory effect seen in the GIA, we have expressed subdomain constructs, in single and doublet combinations, in Escherichia coli, purified each of the proteins, and raised rabbit antibodies against them. These antibodies allowed us to closely examine the effect of domain-specific antibodies on the overall inhibition of invasion measured in the GIA.
MATERIALS AND METHODS
Cloning and expression of the recombinant AMA-1 subdomains. Appropriate PCR primers with 5Ј NcoI and 3Ј NotI restriction sites were designed (Bioserve Biotechnologies, Laurel, Md.) for the gene fragments encoding subdomains I, II, III, IϩII, IIϩIII, and IϩIII (domains as defined by Hodder et al. [13] from the 3D7 isolate of P. falciparum). Gene sequences corresponding to each of these fragments were amplified from a synthetic E. coli codon-optimized AMA-1 ectodomain gene of the 3D7 isolate (encoding amino acids Gly83 to Glu531) (7) by using Taq DNA polymerase and appropriate primers (see Fig. 1 ). To make D IϩIII, gene segments dI and dIII were ligated in a separate ligation reaction before TA cloning. The PCR-amplified products were cloned into TA Cloning Vector pCR r 2.1 (Invitrogen, Carlsbad, Calif.), and positive clones were selected by DNA restriction endonuclease analyses and further confirmed by nucleotide sequence analyses. The expression plasmid (7) was restriction digested with NcoI and NotI, and gel-purified gene inserts from the TA cloning vectors were ligated in before transformation into E. coli strain BL21(DE3). In all cases, insertion into the expression vector resulted in His 6 tags on both the amino-and carboxyterminal ends of the proteins. Bacterial colonies containing expected fragments were picked and analyzed by restriction digestion following plasmid DNA preparation (Qiagen Inc., Valencia, Calif.). Selected clones were further confirmed by nucleotide sequencing of the plasmid DNA samples. Glycerol (8%) stocks were made for each bacterial clone from an overnight culture and stored at Ϫ80°C.
For expression in shake flasks, cells were grown to an optical density at 600 nm of 0.5 and then induced with a final concentration of 0.5 mM isopropyl-␤-Dthiogalactopyranoside (IPTG). Cells were harvested after 2 h of induction by centrifugation at 6,200 ϫ g and 4°C for 30 min. Expression in a 10-liter bioreactor (New Brunswick Scientific, Edison, NJ) used Terrific Broth media (1.2% tryptone, 2.4% yeast extract, 72 mM K 2 HPO 4 , 28 mM KH 2 PO 4 [pH 7.2]) containing 0.8% glycerol and 100 g of ampicillin per ml. The 10 liters of media in the bioreactor was inoculated with 100 ml of an overnight culture, and growth was allowed to proceed at 37°C. pH 7.2 was maintained by controlled addition of either HCl or NaOH. At an optical density at 600 nm of 7 to 8, the temperature was reduced to 25°C and then IPTG was added to a final concentration of 0.5 mM. At 2 h after induction, cells were harvested by centrifugation at 5,000 ϫ g and 4°C for 30 min. Under these conditions, all six constructs had similar growth characteristics. The cell pastes were stored at Ϫ80°C. Aliquots were taken from these for developing the purification conditions for each of the subdomain proteins.
Purification of the subdomain fragments. The E. coli cell pastes were solubilized in a buffer containing 15 mM Na 2 HPO 4 , 5.1 mM KH 2 PO 4 , 450 mM NaCl, and 2.5% sodium N-lauroylsarcosine (Sarkosyl) (pH 7.4) at a concentration of 10 ml of buffer/g of cell paste. The cells were disrupted by a single pass through a high-pressure microfluidizer (model 1109; Microfluidic Corp., Newton, Mass.). Following clarification by centrifugation (12,000 ϫ g, for 45 min at 4°C), supernatants containing the recombinant proteins were incubated by a batch method with nickel nitrilotriacetic acid (Ni-NTA)-agarose chelating resin (0.4 ml of resin/g of cell paste) (Qiagen Inc.) at room temperature (RT) (ϳ22°C) for 1 h in the presence of 35 mM imidazole. The resin was then loaded into a fritted column, and the unbound proteins were allowed to flow through. The resin was washed with a minimum of 40 column volumes (cv) of 20 mM NaHPO 4 -450 mM NaCl-10 mM imidazole-0.125% Sarkosyl (pH 7.4) followed by 10 cv of 20 mM NaHPO 4 -15 mM imidazole (pH 8.0). Bound proteins were eluted with 500 mM imidazole in 20 mM phosphate buffer containing 0.125% Sarkosyl (pH 8.0). Proteins eluted from the Ni-NTA-agarose were rapidly diluted to 30 to 40 g/ml in a redox-coupled GSH-GSSG solution and allowed to fold overnight as described previously (7) . After the refolding period, the protein solution was pH adjusted (to 5.8 for D I and D II, 6.4 for D III, and 6.0 for all double domains) and passed through preequilibrated SP Sepharose (Amersham Pharmacia Biotech) (ϳ0.3 ml of resin/g of cell paste). The resin-bound protein was washed with a minimum of 50 cv of 20 mM NaHPO 4 -1mM EDTA containing 100 mM NaCl (for double-domain constructs) or 250 mM NaCl (for single-domain constructs) at pH 6.0. The bound protein was eluted with 20 mM NaHPO 4 -1 mM EDTA (pH 7.4) plus 150 mM NaCl (pH 6.0) (for single-domain constructs) 300 mM NaCl (pH 6.0) (for D IϩII), or 400 mM NaCl (pH 6.0) (for D IϩIII and D IIϩIII).
Purity. Purity was analyzed on precast 4 to 12% Bis-Tris gels (NuPage; Invitrogen, Carlsbad, Calif.) run as recommended by the manufacturer and stained with Coomassie blue. Additional analysis was carried out by reversed-phase high-performance liquid chromatography (HPLC) using a Waters-510 HPLC pump connected to a Waters-712 WISP auto sampler and controlled by Millennium (Release 3.2) chromatographic software. A Waters 2487 dual absorbance detector was used to monitor the elution profile at 215 and 280 nm. Reversedphase chromatographic analysis was done with a Symmetry 300 C 4 column (pore size, 5 m; 4.6 by 150 mm) (Waters Corp., Milford, Mass.) at a flow rate of 3 ml min Ϫ1 and 10 g of protein per load. Solvent A was 0.1% trifluroacetid acid in H 2 O; solvent B was 0.1% trifluoroacetic acid in acetonitrile. The solvent gradient consisted of 90% solvent A for 5 min, 90% to 10% solvent A over 30 min, 10 to 90% solvent A over 5 min, and reequilibration at 90% A for 10 min. Bovine serum albumin (BSA) and RNase A were used as standards for column resolution.
Molecular mass, reduction and alkylation, and free thiol analyses. Purified domain protein samples were analyzed for mass by matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry (Voyager Biospectrometry PR System; Applied Biosystems) with a sinapinic acid matrix. Lysozyme and cytochrome c were used as mass standards. Protein reduction was achieved by incubation with a 100-fold molar excess of dithiothreitol over cysteines in the presence of 4 M urea, and alkylation was carried out with a 1,000-fold molar excess of iodoacetamide over cysteines for 1 h at room temperature in the dark. Free sulfhydryl groups were estimated in the presence and absence of 4 M guanidine-HCl by using Ellman's reagent (5,5Ј-dithio-bis-3-nitrobenzoic acid). L-Cystine was used to plot the standard curve.
SDS-PAGE and immunoblot analyses. Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using precast 4 to 12% Bis-Tris gels and Western blotted as described previously (7), except that the blots were washed with phosphate-buffered saline plus 0.5% Tween 20 (PBST) and developed with BM Blue POD or nitroblue tetrazolium/5-bromo-4-chloro-3-indolylphosphate (NBT/BCIP; Roche, Indianapolis, Ind.) substrate as recommended by the manufacturer.
Preparation of rabbit sera. Groups of New Zealand White rabbits (n ϭ 3) were immunized subcutaneously with 100 g of each double-domain protein construct emulsified in Montanide ISA-720 (Seppic Inc., Paris, France) as described previously (7) . Research was conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations relating to animals and experiments involving animals. All procedures were reviewed and approved by the Walter Reed Army Institute of Research Institutional Animal Care and Use Committee and performed in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International.
ELISA. Antibody responses were evaluated by enzyme-linked immunosorbent assay (ELISA). Ninety-six-well microtiter plates (Dynax, Chantilly, Va.) were incubated overnight at 4°C with 50 l of a 2-g/ml solution of either AMA-1 ectodomain (7) or individual domain fragments. The plates were blocked at RT for 1 h with PBST containing 5% casein (Sigma, St. Louis, Mo.) and then washed with PBST. Consecutive two-fold dilutions of individual rabbit sera were incubated for 2 h at RT. The plates were washed and incubated with 1:5,000-diluted horseradish peroxidase/alkaline phosphatase-conjugated secondary antibody for 1 h. They were then washed and developed for 30 min with NBT-BCIP-peroxidase substrate (Kirkegaard & Perry Laboratories, Gaithersburg, Md.). The absorbance at 405 nm was recorded, and comparative ELISA titers were calculated using regression analysis on the titration curve. The ELISA was repeated three times for each individual serum sample, in triplicate wells; on separate days.
Competition ELISA. Competition ELISA was done using sera from rabbits immunized with AMA-1 ectodomain (7). This was diluted 1:32,000 and preincubated, with constant mixing, overnight at 4°C with 1 M AMA-1 ectodomain, D I, D II, D III, D IϩII, D IIϩIII, DIϩIII or BSA. The tubes were centrifuged at 18,500 ϫ g for 15 min, and the supernatants were analyzed by ELISA with AMA-1 ectodomain as the capture antigen.
Indirect IFA. Recognition of P. falciparum 3D7 schizonts by anti-AMA1 domain antibodies was analyzed by an indirect immunofluorescence assay (IFA) as described previously (7).
Parasite culture and GIA. P. falciparum (3D7) cultures and GIA were performed as described previously (7, 12) . Briefly, cultures were grown in 48-well plates and kept in suspension culture by rotation on a platform or under static conditions. Control serum or immunoglobulin G (IgG) (dialyzed into RPMINaOH) was added to a final hematocrit of 4%. To assess the antigen specificity of the antibody- Statistical analysis. Microsoft Excel was used to calculate the P values for the two-tailed t tests and the correlation coefficients (r 2 ). For the data presented in Fig. 6 and 7 , estimates of means, confidence intervals, and hypothesis tests were generated using bootstrap. Each of the available data sets was resampled (bootstrapped) 10,000 times. The observed bootstrap probability estimates reported here are consistent with estimates obtained by assuming that bootstrap means and variances are asymptotically normal. The S language for statistical programming (R v1.8.0) was used to develop the bootstrap estimates. Specific language elements used included the "boot" library and the "Marsaglia-Multicarry" random-number generator.
RESULTS
Expression and purification. All six constructs made from the AMA-1 ectodomain were cloned and expressed in E. coli strain BL-21(DE3). The AMA-1 ectodomain construct, D IϩIIϩIII, was made as previously described (7). Figure 1 details the constructs used for individual domains. The biomass yield of a typical 10-liter fermentation was about 400 to 550 g of bacterial paste. All constructs had a His 6 tag, allowing Ni-NTA agarose affinity chromatography as a first step in purification. After refolding, an SP-Sepharose cation-exchange resin was used as a second step of purification, where protein monomers could be separated from multimers using appropriate pH (5.8 to 6.4) and salt concentrations in the wash and elution conditions. This two-step purification yielded Ͼ85% pure recombinant domain proteins, as determined from densitometric scans of SDS-PAGE (Fig. 2) and reversed-phase HPLC (data not shown) analyses. All the subdomain fragments of AMA-1 except D IϩIII resolved into single symmetric peak on a C 4 reversed-phase HPLC column (data not shown). Proteins corresponding to DIII and D IϩIII had a tendency to precipitate at neutral pH when stored at concentrations above 120 g/ml. The two D III-containing constructs could not be assayed using the Ellman test due to solubility problems at the concentration and pH required for the test. As a second test for disulfide bond-stabilized folding, the proteins were subjected to reduction and alkylation followed by SDS-PAGE analysis. The measurements from the Ellman test show that there were, as predicted from the deduced amino acid sequence of the genes, eight disulfide bonds in D IϩIIϩIII, six in D IϩIII, five each in D IϩII and D IIϩIII, three each in D I and D III, and two in D II. All constructs showed significant mobility shifts when subjected to reduction and alkylation (Fig. 2) .
Recognition by antibodies. We used several different experimental conditions to determine the extent of recognition of the domains by antisera made against the entire ectodomain (D IϩIIϩIII). All six recombinant constructs were recognized on Western blots at the appropriate molecular masses by antibodies in a polyclonal rabbit serum raised against D IϩIIϩIII (reference 7 and data not shown) and by a pool of P. falciparum-infected sera collected from western Kenya (Fig. 3) . Constructs D I and D IϩIII were less reactive than the other domains. There was no recognition of these domains in analyses with normal human or rabbit sera at the same concentration (data not shown). MAb 4G2dcl, known to bind to a conformation-dependent epitope within the region encompassing D IϩII (16) , recognized recombinant D IϩII, as shown by Western blotting and ELISA run under nonreduced conditions (data not shown). None of the other constructs were recognized by MAb 4G2dc1 either by ELISA or by Western blotting.
Immune analysis of P. falciparum AMA-1 subdomains. In an ELISA format, about 80% of the antibodies made against the ectodomain were directed against D IϩII (Fig. 4) Recombinant subdomains induce high-titer antibody responses in rabbits. Immunization of rabbits (n ϭ 3) with each of the three double-subdomain fragments induced high-titer antibodies (Table 1) . On indirect IFA, all of these antibodies reacted with schizont forms from P. falciparum 3D7 at a dilution of 1:5,000. The reactivity of rabbit anti-double-domain antibodies with P. falciparum AMA-1 was confirmed by immunoblot analyses. Rabbit antibodies obtained by immunization with all three double-domain constructs (D IϩII, D IIϩIII, and D IϩIII) predominantly recognized two bands (Fig. 5) corresponding to the previously identified 83-and 66-kDa full-length and processed forms of AMA1 in P. falciparum (4, 8, 16, 25) . FIG. 3 . Western blot of each purified construct. A 100-ng amount of each purified nonreduced protein was subjected to SDS-PAGE, electrophoretically transferred to nitrocellulose membranes, and reacted with a pool of sera (diluted 1:1,000) from people who lived in a malaria-endemic area of Western Kenya. MW, molecular weight. Inhibition of P. falciparum invasion of erythrocytes. Purified IgG from the pool of double-domain-immunized rabbit sera was used in the GIA. At 1.0 mg/ml, anti-D IϩIIϩIII inhibited 77% of parasite development and anti-D IϩII resulted in 59% inhibition (Fig. 6 ). At 0.5 mg/ml, these antibodies resulted in 62 and 42% inhibition, respectively. Antibodies against the other domains or IgG purified antibodies from the preimmune sera did not significantly inhibit invasion in the GIA. To investigate the domain specificity of growth-inhibitory antibodies, the GIA was performed with purified anti-D IϩIIϩIII IgG with the addition of recombinant domain proteins to the culture medium (Fig. 7) . The addition of DIϩIIϩIII protein caused Ͼ90% reversal of inhibition in a GIA, and the addition Using two chromatographic columns, procedures were developed that yielded recombinant proteins of Ͼ85% purity. The final yield of recombinant protein per gram of bacterial biomass was two-to threefold higher for D IϩII than for D IϩIIϩIII (7), most probably a reflection of the simpler disulfide bond formations in the smaller construct. It has been show that the disulfide bond-restrained conformation is critical for AMA-1 to induce growth-inhibitory antibodies after vaccination of rabbits (7) . MAb 4G2dc1 has been used as a marker to identify a disulfide bond-dependent conformational epitope in AMA-1 (D IϩIIϩIII). This MAb bound to D IϩII but not to the other single or double domains, indicating that the critical conformational epitope was maintained within D IϩII. Our laboratory has produced seven MAbs against D IϩIIϩIII, all of which were directed against epitopes that required D II. Similar to 4G2dc1, these antibodies were epitope reduction sensitive (A. Barbosa, unpublished data). Although we do not have data about conformation specific MAbs that recognize D I, D III, or D IϩIII, recognition of these proteins by immune sera, mobility shifts on SDS-PAGE after reductive alkylation, sharp-and symmetric peaks on RP HPLC analysis, and the absence of free cysteine content in these preparations indicated that they were homogeneous and correctly folded.
Our data indicate that, using our adjuvant with the proteins in rabbit immunizations, D IϩII is the most immunogenic region within the P. falciparum 3D7 AMA-1 D IϩIIϩIII, while D II is the most immunogenic domain among the three single domains. It is evident from direct and competition ELISA that single domains on their own are less immunogenic than the whole ectodomain. To test the potential of domain-specific antibodies to inhibit invasion in the GIA, we immunized rabbits with the purified double-domain proteins D IϩII, D IIϩIII, and D IϩIII. A positive indirect IFA result with late-stage schizonts of P. falciparum 3D7 parasites and Western blot recognition of the native AMA-1 from parasite lysate with these antibodies suggested a close similarity of these recombinant preparations to the native parasite antigens and the recombinant vaccine construct containing D IϩIIϩIII (7). The ELISA titers were equally high for all three double domains; however, only antibodies from rabbits immunized with the D IϩII construct could significantly inhibit parasite growth in the GIA. A low level of inhibition was measured with antiserum to D IIϩIII, and, although D IϩIII induced high-titer antibodies (titer, 10 6 ), these antibodies were unable to inhibit parasite growth in vitro. These data demonstrated that a portion of the region defined within the recombinant D IϩII induced a majority of the antibodies that are active in the GIA. Hodder et al. (14) suggested that most inhibitory antibodies were directed against D I because that region contained a majority of the amino acid differences seen among three P. falciparum strains (3D7, D10, and HB3) that were inhibited to different degrees in a GIA. Recent studies of D I, the most variable region in AMA-1 (9, 22, 29) , suggested that naturally acquired protective immunity targets domain I (3). D I, in the context of D IϩIII, did not induce any inhibitory antibody, did not significantly inhibit anti-D IϩIIϩIII antisera in the competition ELISA, and did not reverse the growth-inhibitory qualities of anti-D IϩIIϩIII. While the D I amino acid sequence in the D IϩIII construct is 11 amino acid residues shorter then the D I domain alone (due to construction restraints encountered during PCR linking of the gene segments), the data still suggest that only in combination with the D II protein does D I express the structured epitopes that potentially can be blocked by antibody to prevent parasite invasion.
Polyclonal antibodies and MAbs against AMA-1 block the invasion of erythrocytes by merozoites. A majority of the epitopes that induce these inhibitory antibodies are conformational and are destroyed on reduction of the disulfide bonds. Due to the problems of disulfide bond formation with proteins expressed in bacteria, the yield of correctly folded full-length ectodomain in this system is low. This study was initiated, in part, to examine the possibility of using smaller AMA-1 constructs, which may be expressed at high levels in bacteria yet still function as effective malaria vaccines. To that end, this study has demonstrated that subdomains of AMA-1 can be expressed at high levels in E. coli. In addition, we showed that a polypeptide encompassing a region defined by D IϩII can bind most of the antibodies induced on immunization with D IϩIIϩII and that this construct induced potent growth-inhibitory antibodies. However, the overall GIA activity was lower than that observed with antibodies to the D IϩIIϩIII construct. Thus, D III may also contain important protective epitopes. Indeed, recently a virosomal formulation containing a synthetic peptide corresponding to D III of AMA-1 has shown growth-inhibitory activity against parasites (24 
